Gilde Healthcare
en nl de
  • Portfolio
  • Team
  • News
  • About us
  • Contact

News 2011

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Follow @GildeHealthcare

BG Medicine, Inc. Files 510(k) for a diagnostic test to predict heart attacks

December 28, 2011 – WALTHAM, Mass., - BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that it has filed a 510(k) Premarket Notification with the U.S. Food and Drug Administration (FDA) for regulatory clearance…

Related to: BG Medicine

Ablynx Initiates Phase I Study with ALX-0171 for the Treatment of Respiratory Syncytial Virus (RSV)

December 13, 2011 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that it has initiated a Phase I study in healthy volunteers with ALX-0171, the first Nanobody in clinical development to be delivered by inhalation. ALX-0171 is being developed for the treatment of respiratory syncytial…

Related to: Ablynx

Symphogen Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at ASH

December 12, 2011 – COPENHAGEN, Denmark - Symphogen today presented final Phase 2 data demonstrating that its recombinant polyclonal antibody drug candidate rozrolimupab exhibited a favorable safety profile and induced a rapid increase in blood platelets in patients with Immune Thrombocytopenia Purpura…

Related to: Symphogen

Ablynx and Merck Serono Select a Novel Nanobody Candidate, ALX-0761, for Pre-Clinical Development

December 10, 2011 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] and partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that they have advanced the Nanobody candidate, ALX-0761, into pre-clinical development for the treatment of autoimmune diseases. This is the first…

Related to: Ablynx

Acacia Pharma announces positive results from Phase IIa cancer cachexia study

December 6, 2011 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces positive results from its Phase IIa study of APD209 in cancer cachexia. APD209 comprises a new and patent protected use for an oral combination of…

Related to: Acacia Pharma

Inova Labs receives CE Mark Approval for the LifeChoice® Portable Oxygen Concentrator System

December 1, 2011 – New Technology enables COPD patients to experience true portability while maintaining appropriate oxygen concentration levels during both day and night Austin, TX – Inova Labs, a privately held medical device company focused on developing innovative products for the Chronic Obstructive…

Related to: Inova Labs

Ablynx Reports Positive Phase 1 Data for ALX-0061 in Rheumatoid Arthritis

November 30, 2011 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced positive Phase I data from the single ascending dose part of the Phase I/II study with ALX-0061, the anti-IL-6R Nanobody, in patients with rheumatoid arthritis (RA). Based on these positive interim data, Ablynx has…

Related to: Ablynx

Profibrix successfully concludes Phase II clinical trial with Fibrocaps in liver resection surgery

November 17, 2011 – LEIDEN, The Netherlands & SEATTLE, WA, USA - ProFibrix B.V., a leader in the development of innovative products for hemostasis, announced that its multicenter Phase II clinical trial with Fibrocaps in liver resection surgery resulted in a highly statistically significant 50% reduction…

Related to: ProFibrix

AMT Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy

November 16, 2011 – Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency (EMA) has granted orphan designation for its gene therapy program for the treatment of hemophilia B. Orphan…

ProFibrix Phase II with FibrocapsTM Meets Primary Endpoint – On Track for Phase III in 2012

November 15, 2011 – LEIDEN, The Netherlands & SEATTLE -  ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its multicenter Phase II clinical trial with Fibrocaps in liver resection surgery resulted in a highly statistically significant 50% reduction…

Related to: ProFibrix

Gilde Healthcare Partners recruits new partners and opens new office in the US

November 10, 2011 – Utrecht, the Netherlands | Cambridge, USA – Gilde Healthcare Partners a €450 million ($600 million) venture and growth capital group based in Utrecht, Netherlands has announced the opening of its office in Cambridge, MA. The firm’s US investment activity is managed by Geoff Pardo…

ABLYNX and Merck Serono expand their partnership into osteoarthritis

November 9, 2011 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that it has further expanded its relationship with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and entered into a third agreement to co-discover and co-develop Nanobodies® against two targets in osteoarthritis.…

Related to: Ablynx

Gilde Healthcare III makes first investment in Inova Labs

November 8, 2011 – Utrecht, the Netherlands | Cambridge, USA – Gilde Healthcare Partners announced today its first investment via Gilde Healthcare III in Inova Labs (Austin, TX). Inova Labs, a privately held medical device company focused on developing innovative products for the Chronic Obstructive…

Related to: Inova Labs

Santaris Pharma A/S advances the first microRNA-targeted drug to Phase 2 to treat Hepatitis C

November 8, 2011 – Santaris Pharma A/S writes medical history and advances miravirsen, the first microRNA-targeted drug to enter clinical trials, into Phase 2 to treat patients infected with Hepatitis C virus Santaris Pharma A/S Phase 2a data of miravirsen shows dose-dependent, prolonged viral reduction…

Related to: Santaris Pharma

Conatus Pharmaceuticals Appoints Dr. Gary Burgess as Senior Vice President and Chief Medical Officer

November 1, 2011 – SAN DIEGO – Conatus Pharmaceuticals Inc. announced today the appointment of Gary Craig Burgess, M.B., Ch.B. MMed, as Senior Vice President and Chief Medical Officer effective immediately. In this newly created position, Dr. Burgess will oversee all of the company’s clinical development…

Related to: Conatus Pharmaceuticals

Pieris Receives EUR 6 million Grant to Novel Anticalin Therapeutic to Treat Anemia

October 19, 2011 – Freising, Germany - In concert with the award of the EU FP7 Grant to the Pieris-led EUROCALIN Consortium that will enable initial clinical development of Pieris’ proprietary hepcidin antagonist program, the company announced today the positive strategic impact of the grant funding…

Related to: Pieris Pharmaceuticals Inc.

Agendia Announces Completion of Patient Recruitment for International MINDACT Study

October 18, 2011 – BRUSSELS, IRVINE, California, and AMSTERDAM /PRNewswire/ -- The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC 10041/BIG3-04 MINDACT (Microarray In Node negative and 1-3 positive…

Related to: Agendia

Gilde raises additional capital for healthcare service investments

October 13, 2011 – Utrecht - Gilde Healthcare Partners has raised more than €50 million for its Gilde Healthcare Services fund. The fund invests growth capital in specialist clinics, elderly care, primary care, disease prevention, mental health, service laboratories and other healthcare service sectors. “Innovative,…

ProFibrix Completes Enrollment of Phase II Studies with Lead Hemostasis Product Fibrocaps™

September 15, 2011 – LEIDEN, The Netherlands & SEATTLE --(BUSINESS WIRE)-- ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has completed patient enrollment in its two (U.S. and Dutch) prospective, randomized, controlled, multi-center Phase II…

Related to: ProFibrix

Ascendis Pharma reports positive Phase 2 results

September 14, 2011 – Palo Alto, California and Copenhagen, Denmark – Ascendis Pharma, a privately held specialty pharmaceutical company, announced positive results of a Phase 2 clinical study of ACP-001 in growth hormone deficient adults.   The Phase 2 clinical study met all primary and secondary endpoints,…

Related to: Ascendis Pharma

ProFibrix Completes Enrollment of Phase II Study with Fibrocaps

September 14, 2011 – LEIDEN, The Netherlands & SEATTLE - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has completed patient enrollment in its two (U.S. and Dutch) prospective, randomized, controlled, multi-center Phase II studies with lead…

Related to: ProFibrix

Agendia - International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping

August 10, 2011 – Panel’s Recommendations Reinforce Clinical Value of Tests Such as BluePrint­­® IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, a commercial-stage molecular cancer diagnostics company, today announced that the 12th St. Gallen International Breast Cancer Conference (2011) Expert…

Related to: Agendia

mtm laboratories acquired for EUR 190 million

July 19, 2011 – Utrecht, The Netherlands – Gilde Healthcare Partners, a transatlantic investor in Healthcare Technologies and Services, announces the sale of its portfolio company mtm laboratories to Roche (SIX: RO, ROG; OTCQX: RHHBY) for a total consideration of EUR 190 million. Under the terms…

Related to: mtm laboratories

Innate Pharma signs Global License Agreement with BMS, potential deal value up to $465 million

July 7, 2011 – Princeton, New Jersey, and Marseille, France - Bristol-Myers Squibb Company (NYSE: BMY) and Innate Pharma S.A. (Euronext Paris: FR0010331421, IPH) announced a global agreement for the development and commercialization of IPH2102, a novel antibody in Phase I development for the treatment…

Related to: Innate Pharma

Gilde Healthcare II invests in Prosonix Ltd. (Oxford, UK)

July 5, 2011 – UTRECHT, The Netherlands – Gilde Healthcare Partners today announced an investment in Prosonix Ltd. (Oxford, UK), a leader in the development of high value respiratory therapies enabled by its novel and proprietary particle engineering technology.  Alongside Gilde Healthcare Partners,…

Related to: Prosonix

Gilde Healthcare Partners invests in Moximed, Inc.

June 30, 2011 – Utrecht, The Netherlands – Gilde Healthcare Partners today announced an investment in Moximed® Inc  (Hayward, CA, US), a developer of minimally invasive, joint preserving solutions for patients with knee osteoarthritis.  Alongside Gilde Healthcare Partners, new investors Frazier Healthcare…

Related to: Moximed

BG Medicine, Inc. Names Stephen R. Miller Chief Commercial Officer

June 28, 2011 – WALTHAM, Mass. - (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a life sciences company focused on the discovery, development, and commercialization of novel, biomarker-based diagnostics, announced today the appointment of Stephen R. Miller to the newly created position of Chief…

Related to: BG Medicine

Symphogen Presents Preliminary Results from Phase 2 Clinical Trial with Rozrolimupab

June 10, 2011 – Copenhagen, Denmark – Symphogen announced today preliminary data from a phase 2 clinical trial with rozrolimupab (SYM001) in adult, RhD positive, non-splenectomized patients with Immune thrombocytopenia (ITP). The study showed rozrolimupab is well tolerated with no unexpected toxicities…

Related to: Symphogen

Agendia announces details of its planned IPO on NYSE Euronext Amsterdam

June 6, 2011 – Amsterdam, the Netherlands – Agendia, a commercial-stage molecular diagnostics company  with  operations  in  the  Netherlands  and  the  United  States,  today announces  details  of its  planned  initial  public  offering  (the  “IPO”  or  “Offering”)  and contemplated  admission…

Related to: Agendia

Ablynx successfully completes a phase II study and demonstrates clinical proof-of-concept (POC) in p

May 19, 2011 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] announced top-line results from the recently completed POC Phase II clinical trial of ozoralizumab (ATN-103), an anti-TNF-alpha Nanobody licensed to Pfizer, in patients with active rheumatoid arthritis (RA). The study evaluated five…

Related to: Ablynx

Agendia announces colorectal cancer collaboration with Astrazeneca and The Netherlands

May 11, 2011 – AMSTERDAM, THE NETHERLANDS, and IRVINE, CA – Agendia, an innovative molecular cancer diagnostics company, announced that it has partnered with AstraZeneca and The Netherlands Cancer Institute (NKI) to accelerate the development of targeted therapies for colorectal cancer patients.…

Related to: Agendia

Profibrix Raises EUR 15 Million

May 3, 2011 – LEIDEN, THE NETHERLANDS and SEATTLE, US - ProFibrix B.V., a leader in the development of innovative products that help stop bleeding (hemostasis) after surgery, today announced the successful closing of a series B follow-on financing. In conjunction with the financing and to support…

Related to: ProFibrix

Symphogen names new Chief Scientific/Medical and Business Officers Senior Management Team Complete

April 15, 2011 – Copenhagen, Denmark – Symphogen, a private biopharmaceutical company developing superior antibody therapeutics (monoclonal, monoclonal mixtures and polyclonal) to treat cancer, infectious and autoimmune diseases, announced today the completion of its senior management team with the…

Related to: Symphogen

Conatus Pharmaceuticals completes the second closing of its Series B Private Placement Financing

April 12, 2011 – SAN DIEGO – Conatus Pharmaceuticals Inc. announced an additional $7.5 million investment by MPM Capital of South San Francisco, CA. The Series B Preferred Stock financing is now closed with a total of $32.5 million of capital raised. The first closing was completed in early February,…

Related to: Conatus Pharmaceuticals

Pieris signs major collaboration with Daiichi Sankyo

April 12, 2011 – Freising, Germany – Pieris AG announced today the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), under which Pieris will apply its proprietary Anticalin scaffold technology…

Related to: Pieris Pharmaceuticals Inc.

BG Medicine Named To Russell 3000 Investment Index

April 1, 2011 – WALTHAM, Mass., (GLOBE NEWSWIRE) - BG Medicine, Inc. (Nasdaq:BGMD) today announced that it has been added to the Russell 3000® Index, which measures the performance of the 3,000 largest publicly-traded U.S. companies based on total market capitalization. The Russell 3000 Index is…

Related to: BG Medicine

Acacia Pharma Closes $10 Million Investment Round

March 31, 2011 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces it has successfully closed a funding round, raising a total of $10 million. New investor Lundbeckfond Ventures joins Gilde Healthcare in this Series…

Related to: Acacia Pharma

Conatus Pharmaceuticals presents results from a Phase 2 clinical trial of CTS-1027 in HCV genotype 1

March 31, 2011 – SAN DIEGO – Conatus Pharmaceuticals Inc. announced today 24-week interim results from a clinical trial with CTS-1027 in combination with Peginterferon Alpha-2a (Pegasys®) and ribavirin (Copegus®) in a treatment experienced, hepatitis C virus (HCV) null-responder patient population.…

Related to: Conatus Pharmaceuticals

BG MEDICINE announces Research Agreement with Boston Scientific on Cardiovascular Biomarkers

March 30, 2011 – Waltham, MA — BG Medicine, Inc. today announced that it has entered into a research collaboration agreement with Boston Scientific Corporation, a leading medical device manufacturer, to study the role of galectin-3 as an aid in patient screening for cardiac-resynchronization therapy…

Related to: BG Medicine

Study of CINtec® PLUS in the management of Pap negative but HPV positive women published

March 28, 2011 – Paper in Gynecologic Oncology shows that p16/Ki-67 dual staining can pinpoint those women that need immediate follow-up Heidelberg, Germany - mtm laboratories announced the publication of study results showing that the CINtec® PLUS kit for dual staining of p16 and Ki-67 is an effective…

Related to: mtm laboratories

Chroma Therapeutics enters collaboration with Cell Therapeutics Inc

March 14, 2011 – Oxford, UK and Seattle, US – Chroma Therapeutics Ltd and Cell Therapeutics, Inc. (“CTI”) (NASDAQ and MTA: CTIC) announced that the companies have entered into a co-development and license agreement providing CTI with exclusive marketing and co-development rights to Chroma’s drug candidate…

Related to: Chroma Therapeutics

Conatus Pharmaceuticals Will Display Hcv Clinical Trial Data At The International Liver Congress

March 11, 2011 – SAN DIEGO – Conatus Pharmaceuticals Inc. today announced the acceptance of two poster presentations of Phase 2 clinical trial data of CTS-1027 for the treatment of hepatitis C virus-infected patients at the 46th annual meeting of the European Association for the Study of the Liver…

Related to: Conatus Pharmaceuticals

Profibrix initiates phase II with lead hemostasis product Fibrocaps in US and Europe

March 8, 2011 – Leiden, The Netherlands and Seattle, WA – ProFibrix B.V., a leader in the development of innovative products for hemostasis, announced that it has initiated a prospective, multi-center Phase II study with its lead product Fibrocaps at up to 20 sites, including major U.S. and Dutch…

Related to: ProFibrix

Pieris to Present Interim Data from the Phase I Clinical Trial of PRS-050 at Molecular Medicine

February 22, 2011 – Freising, Germany — Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin® program, currently under evaluation for the treatment of cancer. Dr. Laurent Audoly, Chief Scientific Officer of Pieris, will…

Related to: Pieris Pharmaceuticals Inc.

Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial Of Cts-1027 For The Treatment

February 17, 2011 – SAN DIEGO — Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a (Pegasys®) and ribavirin (Copegus®) in a treatment experienced, hepatitis C (HCV) null…

Related to: Conatus Pharmaceuticals

BG Medicine Announces Issuance of United States Patent for Galectin-3 Testing in Heart Failure

February 16, 2011 – WALTHAM, MA - BG Medicine (NASDAQ: BGMD), a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers, today announced the issuance of U.S. Patent No. 7,888,137, entitled "Method For Identifying a Subject at Risk of…

Related to: BG Medicine

Acacia Pharma initiates Phase IIa clinical trial with APD421 for nausea & vomiting

February 16, 2011 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces it has initiated a dose-escalating, Phase IIa proof-of-concept study of its product candidate APD421. APD421 is an intravenous formulation of a currently…

Related to: Acacia Pharma

Conatus Pharmaceuticals Raises $20 Million

February 14, 2011 – SAN DIEGO  – Conatus Pharmaceuticals Inc. announced the closing of a $20 million Series B Preferred Stock private placement financing. This financing was led by new investor, AgeChem Venture Fund of Montreal, Canada, and included participation by existing investors; Aberdare Ventures,…

Related to: Conatus Pharmaceuticals

BG Medicine exercises over-allotment option and closing of IPO

February 14, 2011 – WALTHAM, Mass. - BG Medicine (NASDAQ: BGMD) announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG Medicine’s common stock at $7.00 per share, less underwriting discounts and…

Related to: BG Medicine

Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing

February 11, 2011 – SAN DIEGO – Conatus Pharmaceuticals Inc. today announced the closing of a $20 million Series B Preferred Stock private placement financing. This financing was led by new investor, AgeChem Venture Fund of Montreal, Canada, and included participation by existing investors; Aberdare…

Related to: Conatus Pharmaceuticals

Acacia Pharma Completes Phase I Clinical Trial In Xerostomia

February 7, 2011 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces it has completed a Phase I clinical study of its product candidate APD515, an optimised oromucosal formulation of a currently marketed drug for the…

Related to: Acacia Pharma

BG Medicine Announces Pricing of Initial Public Offering at NASDAQ

February 4, 2011 – WALTHAM, Mass. - BG Medicine (NASDAQ: BGMD) today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price of $7.00 per share, before underwriting discounts and commissions. All shares are being sold by the Company. The shares are expected…

Related to: BG Medicine

AMT Receives a Third of €3.3M EU Grant for Clinical Development of Gene Therapy

February 1, 2011 – Amsterdam Molecular Therapeutics (AMT) will receive €1.1 million (about $1.5 million) of a €3.3 million (approximately $4.5 million) grant being awarded by the European Union 7th Framework Program (FP7) to the AIPGENE consortium, which is working to develop a gene therapy product…

BG Medicine Announces Nationwide Availability of Galectin-3 Testing Service through LabCorp

January 18, 2011 – WALTHAM, Mass. --(BUSINESS WIRE)-- BG Medicine announced today that Laboratory Corporation of America®Holdings (LabCorp®)now offers galectin-3 testing services using the BGM Galectin-3 test for heart failure. The BGMGalectin-3 test was cleared by the FDA in November 2010 as an aid…

Related to: BG Medicine

Takeda San Francisco and Pieris Sign Anticalin® Therapeutic Collaboration

January 10, 2011 – San Francisco, USA and Freising-Weihenstephan, Germany — Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin® scaffold technology to deliver protein therapeutic candidates to Takeda, both companies…

Related to: Pieris Pharmaceuticals Inc.

Symphogen Raises EUR 100 Million, The Largest Private Round In European Biotech Ever

January 6, 2011 – UTRECHT, Netherlands – Symphogen, a private biopharmaceutical company developing superior antibody therapeutics (monoclonal, monoclonal mixtures and polyclonal) to treat cancer, infectious and autoimmune diseases, announced that it closed a €100 million placement of Preferred Stock…

Related to: Symphogen

BG Medicine and Siemens Healthcare Diagnostics to Develop Galectin-3 Test

January 6, 2011 – Waltham, MA— BG Medicine, Inc. announced today that it has entered into an agreement with Siemens Healthcare Diagnostics Inc., a division of Siemens Healthcare, one of the world’s largest suppliers of clinical diagnostics to the healthcare industry, for the development and commercialization…

Related to: BG Medicine

Gilde Healthcare

Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare's venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare's private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.

Investment Philosophy

Gilde Healthcare invests in fast growing, innovative businesses delivering better care at lower cost.

  • Home
  • Portfolio
  • Team
  • News
  • Contact
  • Imprint
  • Privacy Policy
  • SFDR Disclosure